Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Max Gelman

Senior Editor

Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in Barcelona this weekend as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Max Gelman

Senior Editor

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?

Nu­va­tion Bio to head to FDA with pooled ROS1-pos­i­tive lung can­cer da­ta

Max Gelman

Senior Editor

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?